Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01572987 · ClinicalTrials.gov registry record · NA
Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus
A NA study, sponsored by Midwest Biomedical Research Foundation.
- Terminated
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT01572987 is a NA study that was terminated before completion, run by Midwest Biomedical Research Foundation. The registered enrollment target is 12 participants.
The verdict
NCT01572987, a NA study, was terminated before completion, sponsored by Midwest Biomedical Research Foundation.
- TERMINATED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
This clinical trial will evaluate a patient population with Barrett's esophagus(BE) containing high grade dysplasia or intramucosal cancer and compare the effects of endoscopically-guided radiofrequency ablation system(RFA) and endoscopically-guided stepwise endoscopic mucosal resection(S-EMR).
Interventions
- DEVICE Radiofrequency Ablation(RFA) by HALO device.
- DEVICE Endoscopic mucosal resection(EMR) by mucosectomy kit.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-09 |
| Est. Completion | 2017-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01572987
The ClinicalTrials.gov registry entry for NCT01572987 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Midwest Biomedical Research Foundation, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiofrequency Ablation(RFA) by HALO device. is the first listed.
NCT01572987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01572987 about?
NCT01572987 is a clinical study titled "Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus". This clinical trial will evaluate a patient population with Barrett's esophagus(BE) containing high grade dysplasia or intramucosal cancer and compare the effects of endoscopically-guided radiofrequency ablation system(RFA) and endoscopically-guided stepwise endoscopic mucosal resection(S-EMR).
What is the current status of trial NCT01572987?
This trial is currently terminated. It is a NA study. The enrollment target is 12 participants. The study started on 2011-09. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01572987?
The interventions under investigation include: Radiofrequency Ablation(RFA) by HALO device. (DEVICE), Endoscopic mucosal resection(EMR) by mucosectomy kit. (DEVICE).
Who is sponsoring clinical trial NCT01572987?
This trial is sponsored by Midwest Biomedical Research Foundation, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.